Facebook
X
LinkedIn
Forward61th Annual Clinical Diabetes and Endocrinology Institute Snowmass 2026
This live activity will provide educational content, clinical cases and practical strategies to increase learners' knowledge base regarding assessment and treatment of patients with endocrine and/or metabolic disorders. Patient-centered team-based care, interprofessional communication, and roles/responsibilities of multidisciplinary teams providing endocrine/metabolic care will also be discussed as these relate to care of patients with endocrine and/or metabolic disorders.
Target Audience
This activity is designed for an audience of physicians, Nurses, Physicians Assistants, Pharmacist and Nurse Practitioners.
Learning Objectives
Explain the use of incretins in diabetes and in obesity.
Apply evidence to design appropriate management plans for menopause.
Demonstrate how to personalize management of toxic thyroid nodules.
Communicate the overarching paradigm of what is known about the gut microbiome in obesity and in diabetes.
Describe relevant changes in the guidelines for thyroid nodule evaluation and management.
Discuss the use of newer medications in the treatment for elevated lipoprotein(a) and other lipoprotein metabolism disorders.
Integrate information from challenging bone cases into clinical practice.
Implement sequential therapy of osteoporosis medications according to available evidence.
Debate the pros and cons of GLP1-based therapies in the management of diabetes.
Explain the evaluation and management of polycystic ovary syndrome across the lifespan.
Demonstrate the use and interpretation of diabetes technology in type 1 diabetes.
Implement therapeutics for diabetes in pregnancy.
Communicate advances in pathophysiology and management of congenital adrenal hyperplasia.
Discuss challenges in contemporary diabetes management.
Identify potential situations in which androgen doping should be suspected.
Describe practical strategies for managing obesity.
Explain approaches to management of endocrine complications of oncologic therapy.
Review the evidence for inpatient use of zoledronic acid and Fracture Liaison Services.
Discuss the differential diagnosis and treatment implications for hyperprolactinemia.
Explain contemporary approaches to metabolic bone disease and use of imaging.
Integrate key information from thyroid cases into clinical practice.
Determine optimal treatment strategies in premenopausal osteoporosis.
Explain gaps in current guidelines for evaluation and management of thyroid and parathyroid disorders in pregnancy.
Discuss the use of artificial intelligence and genetic risk to improve thyroid cancer diagnosis.
Employ cardiovascular imaging to stratify cardiovascular risk and determine optimal lipid management.
Commercial Support
There is no commercial support for this activity.
Faculty/speakers here...
Planners and Reviewers
Dorothy Caputo, MA, BSN, RN (President, AKH Inc.)
Michele Bielarski, RN (Reviewer)
Rebecca Ann Lakofsky, BSN (Reviewer)
Dorothy Duffy, RPh (Reviewer)
Risha Bellomo PA-C (Reviewer)
Bernadette Makar, MSN, APRN-BC, NP-C (Reviewer)
Donna Purcell, Psy.D (Reviewer)
Broc Pollinger, MSW, LSW, OSW-C (Reviewer)
Deborah Cooper, RD, LDN (Reviewer)
AKH Inc Staff and Planners
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Clinical Endocrine Institute. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 18.50 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 18.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 18.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Pharmacists
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 18.50 contact hours.
Nursing
Credit being awarded: 18.50 ANCC contact hours
Physician Associates
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 18.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioners
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Clinical Endocrine Institute. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 18.50 contact hours.
Available Credit
- 18.50 AANP
- 18.50 AAPA Category 1 CME
- 18.50 ABIM Medical Knowledge
- 18.50 ACPE Pharmacist
- 18.50 AMA PRA Category 1 Credit™
- 18.50 ANCC
- 18.50 Attendance